Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

2061. Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus

Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Chilcott J B, Whitby S M, Moore R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was renal transplantation. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised both diabetic and nondiabetic patients, who were aged 15 to 55 years and underwent renal transplantation. Setting The setting was a hospital. The economic study was carried out

2001 NHS Economic Evaluation Database.

2062. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2001 NHS Economic Evaluation Database.

2063. Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands

Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Hutubessy R C, Vondeling H, de Sonnaville J J, Colly L P, Smit J L, Heine R J Record Status This is a critical abstract (...) for the management of patients with Type 2 diabetes initiating insulin therapy. The service consisted of a patient registration and recall system plus a laboratory. A dietician and a specific diabetes educator provided diabetes education. A supervising diabetologist could be consulted by telephone 24 hours a day. The patients were monitored at least at 3-month intervals and feedback was provided to the GP. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

2064. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)

An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions under study were two antihypertensive therapies, atenolol (a beta-blocker, daily dose of 50 mg, increasing to 100 mg if required) and captopril (an angiotensin converting enzyme inhibitor (ACE), 25 mg twice daily increasing to 50 mg twice daily), in patients with type-2 diabetes. Type

2001 NHS Economic Evaluation Database.

2065. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting

. Other issues The authors compared their results with similar studies obtained for the management of Type 1 diabetes. The issue of generalisability to settings other than Switzerland was not explicitly addressed. The model only considered some aspects of diabetes and a selection of specific treatments. The authors acknowledged that other complications, such as diabetic neuropathy, diabetic foot syndrome, and diabetes-related infections were not considered in the model. In addition, the economic (...) of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000;43:13-26. Indexing Status Subject indexing assigned by NLM MeSH Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /economics /prevention & Disease Management; Female; Humans; Life Expectancy; Male; Middle Aged; Patient Education as Topic; Risk Factors; Switzerland /epidemiology; control /therapy AccessionNumber 22001001531 Date bibliographic record published 31/12/2002

2001 NHS Economic Evaluation Database.

2066. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data The ACE (...) treatment regimes were included: captopril, 12.5 to 50 mg, twice daily; lisinopril, 10 to 20 mg/day; enalapril, 10 to 20 mg/day; perindopril, 2 mg/day; and ramipril, 1.25 or 5 mg/day. The treatment duration, where reported, ranged from 0 to 52 years. Participants included in the review Non-hypertensive patients with type 1 diabetes mellitus, as defined by the individuals trials, were eligible for inclusion. Patients could only have microalbuminuria, which was defined as an albumin excretion rate of 20

2001 DARE.

2067. Fish oil in people with type 2 diabetes mellitus. (Abstract)

Fish oil in people with type 2 diabetes mellitus. People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary fish oils are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outcomes are not well known.To determine the effects of fish oil supplementation on cardiovascular outcomes, cholesterol levels and glycemic control in people with type 2 diabetes mellitus.We carried out a comprehensive search (...) of the Cochrane Controlled Trials Register, Medline, Embase, Lilacs, bibliographies of relevant papers and contacted experts for identifying additional trials. Date of last search: September 2000.All randomized placebo-controlled trials in which fish oil supplementation was the only intervention in people with type 2 diabetes were included. Authors were contacted for missing information.Three investigators performed data extraction and quality scoring independently with discrepancies resolved

2001 Cochrane

2068. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. (Abstract)

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Most antidiabetic agents target only 1 of several underlying causes of diabetes. The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patients with type 2 diabetes; therefore, their combined use may be indicated for patients whose diabetes is poorly controlled by metformin (...) alone.To evaluate the efficacy of metformin-rosiglitazone therapy in patients whose type 2 diabetes is inadequately controlled with metformin alone.Randomized, double-blind, placebo-controlled trial from April 1997 and March 1998.Thirty-six outpatient centers in the United States.Three hundred forty-eight patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body mass index of 30.1 kg/m2 were

2000 JAMA Controlled trial quality: predicted high

2069. Guidance on rosiglitazone for Type 2 diabetes mellitus

Guidance on rosiglitazone for Type 2 diabetes mellitus Guidance on rosiglitazone for Type 2 diabetes mellitus Guidance on rosiglitazone for Type 2 diabetes mellitus National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on rosiglitazone for Type 2 diabetes mellitus. London (...) : National Institute for Clinical Excellence (NICE) 2000 Authors' objectives To provide guidance on the use of rosiglitazone for Type 2 diabetes mellitus. Authors' conclusions Guidance 1.1 Rosiglitazone is effective at reducing blood glucose when added to oral monotherapy (metformin or sulphonylurea) for patients who have inadequate control of blood glucose on these conventional agents alone. 1.2 Patients with inadequate blood glucose control on oral monotherapy (metformin or sulphonylurea) should first

2000 Health Technology Assessment (HTA) Database.

2070. Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients

Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Pons JM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pons JM (...) . Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN01/2000. 2000 Authors' objectives To review the available evidence on continuous subcutaneous infusion of insulin with portable pump in diabetes type I patients. Authors' conclusions Continuous subcutaneous external infusion insulin pumps were found to be effective to achieve good metabolic control, the closest

2000 Health Technology Assessment (HTA) Database.

2071. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. (Abstract)

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Oral administration of autoantigens can slow the progression of beta-cell destruction in non-obese diabetic mice. We investigated whether oral administration of recombinant human insulin could protect residual beta-cell function in recent-onset type 1 diabetes.We enrolled 131 autoantibody-positive diabetic patients aged 7-40 years (...) concentration at entry influenced treatment effects. No differences were seen in the time-course or titres of antibodies to insulin, glutamic acid decarboxylase, or islet antigen 2.At the doses used in this trial, oral administration of insulin initiated at clinical onset of type 1 diabetes did not prevent the deterioration of beta-cell function.

2000 Lancet Controlled trial quality: predicted high

2072. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. Full Text available with Trip Pro

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. To estimate the cost effectiveness of conventional versus intensive blood glucose control in patients with type 2 diabetes.Incremental cost effectiveness analysis alongside randomised controlled trial.23 UK hospital clinic based study centres.3867 patients with newly diagnosed type 2 (...) with type 2 diabetes significantly increased treatment costs but substantially reduced the cost of complications and increased the time free of complications.

2000 BMJ Controlled trial quality: uncertain

2073. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. (Abstract)

Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. The effect of increasing the intake of dietary fiber on glycemic control in patients with type 2 diabetes mellitus is controversial.In a randomized, crossover study, we assigned 13 patients with type 2 diabetes mellitus to follow two diets, each for six weeks: a diet containing moderate amounts of fiber (total, 24 g; 8 g of soluble fiber and 16 g of insoluble fiber), as recommended by the American (...) ) and 12 percent (P=0.05), respectively. The high-fiber diet reduced plasma total cholesterol concentrations by 6.7 percent (P=0.02), triglyceride concentrations by 10.2 percent (P=0.02), and very-low-density lipoprotein cholesterol concentrations by 12.5 percent (P=0.01).A high intake of dietary fiber, particularly of the soluble type, above the level recommended by the ADA, improves glycemic control, decreases hyperinsulinemia, and lowers plasma lipid concentrations in patients with type 2 diabetes.

2000 NEJM Controlled trial quality: uncertain

2074. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23(7): 888-892 PubMedID Original Paper URL Other publications of related interest 1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71. 2. Cochran WG. Some methods for strengthening the common chi-square tests. Biometrics 1954;10:417-51. Indexing Status Subject indexing assigned by NLM MeSH (...) Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Pahor M, Psaty B M, Alderman M H, Applegate W B, Williamson J D, Furberg C D Authors' objectives To assess whether angiotensin-converting enzyme (ACE) inhibitors and other hypertensive

2000 DARE.

2075. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Vijan S, Hofer T P, Hayward R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening intervals for diabetic retinopathy in patients with Type 2 diabetes mellitus. Type of intervention Screening. Economic study type Cost-utility analysis. Study population Hypothetical patients based on the US population of diabetic patients older than 40 years from the Third National Health and Nutrition

2000 NHS Economic Evaluation Database.

2076. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive insulin therapy for type 2 diabetes in Japan. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of Japanese patients with type 2 diabetes. Setting The setting was a hospital

2000 NHS Economic Evaluation Database.

2077. [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics]

[Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Analisis coste-efectividad de la automonitorizacion de la glucosa sanguinea en diabeticos tipo 2 [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Analisis coste-efectividad de la automonitorizacion de la glucosa sanguinea en diabeticos tipo 2 [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Clua Espuny J L, Puig Junoy J, Queralt Tomas M (...) L, Palau Galindo A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The self-monitoring of capillary blood glucose (MBG) by Type 2 diabetes patients using reagent strips was studied. Type of intervention Secondary prevention

2000 NHS Economic Evaluation Database.

2078. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective Full Text available with Trip Pro

the effects of insulin therapy in more detail. Source of funding Partially funded by research grants from Roche Diagnostics Schweiz AG and Roche Diagnostics Boehringer Mannheim GmbH. Bibliographic details Palmer A J, Weiss C, Sendi P P, Neeser K, Brandt A, Singh G, Wenzel H, Spinas G A. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43(1): 13-26 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Albuminuria; Cost (...) -Benefit Analysis; Diabetes Mellitus, Type 1 /economics /physiopathology /therapy; Diabetic Angiopathies /prevention & Diabetic Nephropathies /epidemiology /prevention & Diabetic Retinopathy /epidemiology /prevention & Humans; Incidence; Insulin /economics /therapeutic use; Kidney Failure, Chronic /prevention & Life Expectancy; Markov Chains; Mass Screening; Models, Statistical; Switzerland; control; control; control; control AccessionNumber 22000000308 Date bibliographic record published 30/04/2001

2000 NHS Economic Evaluation Database.

2079. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes

, Sendi P P, Spinas G A. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische Medizinische Wochenschrift 2000; 130(27-28): 1034-1040 PubMedID Other publications of related interest 1. UKPDS Group. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 1991;34:877-90. 2. UKPDS Group. Effect (...) Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost

2000 NHS Economic Evaluation Database.

2080. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes

-effectiveness. Source of funding Supported by Parke-Davis, Ann Arbor (MI), USA. Bibliographic details Caro J J, Klittich W S, Raggio G, Kavanagh P L, O'Brien J A, Shomphe L A, Flegel K M, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes. Clinical Therapeutics 2000; 22(1): 116-127 PubMedID Other publications of related interest Eastman R, Javitt J, Herman W, et al. Model of complications of NIDDM.I. Model construction (...) Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Caro J J, Klittich W S, Raggio G, Kavanagh P L, O'Brien J A, Shomphe L A, Flegel K M, Copley-Merriman C, Sigler C Record Status This is a critical abstract

2000 NHS Economic Evaluation Database.